Lupus Nephritis Trials
The Division of Rheumatology strives to understand more about lupus through research. Please see the list below, which summarizes the studies available to individuals interested in advancing our understanding and treatment of rheumatic disease.
| Study Name/IRB#/PI | Brief Description | Basic Eligibility Criteria | Contact |
VIBRANT IRB# 22-0596 Amber Podoll, MD | VIBRANT is a phase 2a double-blind, placebo-controlled trial investigating the efficacy and safety of VIB4920 combined with MMF in patients with active lupus nephritis. Eligible participants will be randomized to receive IV VIB4920 1500 mg or placebo at Weeks 0, 2, 4, 8, 12, 16, 20, and 24. 1000mg IV methylprednisolone will be given at Week 0. Participants will also begin MMF 2-3 g/day and prednisone 25 mg/day at Week 0, with prednisone tapered to ≤ 5 mg/day by Week 8. | Inclusion:
Exclusion:
| 303-724-7790 or |
Please note that study status changes frequently and therefore, a listed study may not be actively enrolling. Also, the complete list of inclusion and exclusion criteria for a given study is often not listed due to its length. A visit to determine an individuals eligibility may be required. A placebo is an inactive substance or treatment that looks the same as, and is given the same way as, an active drug or treatment being tested. The effects of the active drug or treatment are compared to the effects of the placebo.